https://bio.nikkeibp.co.jp/atcl/news/p1/26/03/05/14323/

Euglena Co. is embarking on the development of food for patients with specific diseases. The company aims to sell food for chronic kidney disease (CKD) using paramylon, an insoluble polysaccharide produced by euglena, as its active ingredient. The company calls the food “medical food,” and is exploring the appropriate framework for foods that claim to slow the progression of specific diseases.

Paramylon is a molecule formed by the helical structure of β1,3-glucan, a polysaccharide in which glucose units are linked in a linear chain via β1,3 bonds, forming granules. Paramylon accounts for approximately 30-40% of the substances contained in Euglena cells, and its extraction and purification can produce paramylon powder.